[{"address1": "301 - 1665 Ellis Street", "city": "Kelowna", "state": "BC", "zip": "V1Y 2B3", "country": "Canada", "phone": "833-811-8797", "website": "https://www.tryptherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jim  O'Neill", "title": "Chief Financial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.", "age": 74, "title": "Chief Medical Officer", "yearBorn": 1949, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0333, "open": 0.0243, "dayLow": 0.0041, "dayHigh": 0.0275, "regularMarketPreviousClose": 0.0333, "regularMarketOpen": 0.0243, "regularMarketDayLow": 0.0041, "regularMarketDayHigh": 0.0275, "beta": -1.128, "volume": 180850, "regularMarketVolume": 180850, "averageVolume": 40505, "averageVolume10days": 29867, "averageDailyVolume10Day": 29867, "marketCap": 2848430, "fiftyTwoWeekLow": 0.0041, "fiftyTwoWeekHigh": 0.0919, "fiftyDayAverage": 0.033013, "twoHundredDayAverage": 0.04703715, "currency": "USD", "enterpriseValue": 4279264, "floatShares": 51335589, "sharesOutstanding": 96419296, "heldPercentInsiders": 0.47248, "impliedSharesOutstanding": 206408000, "bookValue": -0.052, "lastFiscalYearEnd": 1693440000, "nextFiscalYearEnd": 1725062400, "mostRecentQuarter": 1701302400, "netIncomeToCommon": -4793340, "trailingEps": -0.03, "52WeekChange": -0.8135135, "SandP52WeekChange": 0.22591555, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "TRYPF", "underlyingSymbol": "TRYPF", "shortName": "TRYP THERAPEUTICS INC", "longName": "Tryp Therapeutics Inc.", "firstTradeDateEpochUtc": 1612794600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9cb12462-7365-35fe-9d45-06c6b7e87d95", "messageBoardId": "finmb_693911067", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0138, "recommendationKey": "none", "totalCash": 2064213, "totalCashPerShare": 0.021, "totalDebt": 5012890, "quickRatio": 0.303, "currentRatio": 0.313, "returnOnAssets": -1.4038299, "freeCashflow": -1802319, "operatingCashflow": -3620152, "financialCurrency": "CAD", "trailingPegRatio": null}]